NCT00021567 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Iseman MD
Mycobacterium avium complex and the normal host: the other side of the coin. N Engl J Med. 1989 Sep 28;321(13):896-8.
Meissner PS, Falkinham JO 3rd
Plasmid DNA profiles as epidemiological markers for clinical and environmental isolates of Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium scrofulaceum. J Infect Dis. 1986 Feb;153(2):325-31.
Wolinsky E
Mycobacterial diseases other than tuberculosis. Clin Infect Dis. 1992 Jul;15(1):1-10. Review.

A Randomized, Double-Blinded, Placebo-Controlled, Phase II Study of the Safety and Efficacy of Inhaled Interferon Gamma-1b With Antimycobacterial in Previously Treated or Moderate to Severe Pulmonary Mycobacterium Avium Complex (MAC) Infection

Details for clinical trial NCT00021567

Clinical trial NCT00021567 - References